Gene-Targeted Agent Brings Clinical Benefit In R/R Acute Leukemias Oncology Times - OncTimes Talk podcast

Artwork

Medicine Oncology Cancer Oncology Times Science News Health and Well-Being

Indhold leveret af Oncology Times. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Oncology Times eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Oncology Times - OncTimes Talk « »
Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias

3M ago 24:23

Del

Indhold leveret af Oncology Times. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Oncology Times eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

A new targeted drug, revumenib, was found to increase response rates and survival in patients whose previously treated acute leukemias relapsed or were refractory to treatment. A Phase II clinical study found revumenib met its primary endpoint and was stopped early because of a high patient response rate and clinical efficacy.

Revumenib acts on the hitherto untargeted histone-lysine N-methyltransferase 2A (KMT2A)-rearranged gene, which is present in around 1 in 10 acute leukemias among patients of all ages. The drug inhibits the interaction of the protein menin (associated with tumor suppression) and the KMT2A-fusion protein, which is believed to be an oncogenic driver in leukemias.

OncTimesTalk correspondent Peter Goodwin heard the latest from lead study author Ibrahim Aldoss, MD, Associate Professor in the Division of Leukemia of the Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope, after his report to the 65th ASH Annual Meeting & Exposition.

… continue reading

139 episoder

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Artwork

Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias

Oncology Times - OncTimes Talk

21 subscribers

published 3M ago

Del

Indhold leveret af Oncology Times. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Oncology Times eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

A new targeted drug, revumenib, was found to increase response rates and survival in patients whose previously treated acute leukemias relapsed or were refractory to treatment. A Phase II clinical study found revumenib met its primary endpoint and was stopped early because of a high patient response rate and clinical efficacy.

Revumenib acts on the hitherto untargeted histone-lysine N-methyltransferase 2A (KMT2A)-rearranged gene, which is present in around 1 in 10 acute leukemias among patients of all ages. The drug inhibits the interaction of the protein menin (associated with tumor suppression) and the KMT2A-fusion protein, which is believed to be an oncogenic driver in leukemias.

OncTimesTalk correspondent Peter Goodwin heard the latest from lead study author Ibrahim Aldoss, MD, Associate Professor in the Division of Leukemia of the Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope, after his report to the 65th ASH Annual Meeting & Exposition.

… continue reading

139 episoder

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

All episodes

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner